About this Research Topic
Inflammatory bowel disease (IBD) is a group of devastating auto-immune disorders that primarily includes ulcerative colitis and Crohn's disease, which also raises the risk of colitis-related cancer. Gastrointestinal inflammation and tumors develop in the intricate tissue microenvironment, which requires sustained growth and metastasis. In the inflammation tumor microenvironment (TME), immunosuppressive cells including immune cells, cancer-associated fibroblasts (CAFs), mesenchymal stromal cells (MSCs), and others, could promote tumor immune escape by suppressing antitumor immune responses and furthermore facilitate establishing a tumor-promoting niche by inducing immunosuppression, cell proliferation, invasion, epithelial-mesenchymal transition (EMT), and angiogenesis. Of note, the relative biomarkers of gastrointestinal inflammation and tumor progression are numerous and have the potential to significantly influence patient outcomes. Therefore, it is crucial to investigate the function of tumor biomarkers as therapeutic targets in gastrointestinal tumor processes and to develop new and effective therapeutic approaches.
Even though there are many tumor markers, the number of key markers that can affect the tumor process and that can be applied in the clinic is limited. This topic aims to identify molecules that have a significant impact on the gastrointestinal tumor process and that may help in the development of new therapeutic strategies.
The scope of the Research Topic includes but is not limited to:
• Gastrointestinal tumors
• Microenvironmental factors and molecular mechanisms of tumor progression
• Cytokines and metastatic properties of carcinoma cells
• Role of carcinoma stem cells in tumor formation
• Immune system and tumor development
• Molecular mechanisms regulating therapy response of tumor lesions
• Novel therapeutic approaches to prevent and/or combat IBD and its associated tumor
• Exosomes in the regulation of diverse processes of IBD and its associated tumor
• Immunotherapy in different courses of tumor patients
• Biomarkers as therapeutic targets in gastrointestinal tumor processes
Please note that clinical studies and manuscripts describing purely bioinformatic analyses of existing databases without significant experimental validation will not be accepted to this collection, as they are outside the scope of the Preclinical Cell and Gene Therapy section, of which this Research Topic is a part.
Even though there are many tumor markers, the number of key markers that can affect the tumor process and that can be applied in the clinic is limited. This topic aims to identify molecules that have a significant impact on the gastrointestinal tumor process and that may help in the development of new therapeutic strategies.
The scope of the Research Topic includes but is not limited to:
• Gastrointestinal tumors
• Microenvironmental factors and molecular mechanisms of tumor progression
• Cytokines and metastatic properties of carcinoma cells
• Role of carcinoma stem cells in tumor formation
• Immune system and tumor development
• Molecular mechanisms regulating therapy response of tumor lesions
• Novel therapeutic approaches to prevent and/or combat IBD and its associated tumor
• Exosomes in the regulation of diverse processes of IBD and its associated tumor
• Immunotherapy in different courses of tumor patients
• Biomarkers as therapeutic targets in gastrointestinal tumor processes
Please note that clinical studies and manuscripts describing purely bioinformatic analyses of existing databases without significant experimental validation will not be accepted to this collection, as they are outside the scope of the Preclinical Cell and Gene Therapy section, of which this Research Topic is a part.
Keywords: IBD therapy, molecular mechanisms, immunology, Inflammatory bowel disease, tumor, inflammation, auto-immune disorders, microenvironmental factors, biomarkers
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
